Close Window
Aetna Medicare
Aetna Aetna
Pharmacy Clinical Policy Bulletins
Aetna Medicare Prescription Drug Plan
Subject: Antipsoriatics

Status Drug PR-B/D PR PR-QL PR-AL ST M EX‡ TOC§
C calcipotriene solution              
C Tazorac®  (tazarotene)              
CS 8-MOP®  (methoxsalen)              
CS Oxsoralen-UL®  (methoxsalen capsule)              
CS Soriatane CK Kit®  (acitretin w/moisturizer kit)              
NC Dovonex®  (calcipotriene)           X  
NC Oxsoralen®  (methoxsalen lotion)           X  
NC Taclonex®  (calcipotriene/betamethasone)         X X  
NC Taclonex Scalp™  (calcipotriene/betamethasone)         X X  
NC Vectical™  (calcitriol)         X X  


Policy:

  1. Step Therapy Criteria
  2. Under some plans, including plans that use an open or closed formulary, Taclonex, Taclonex Scalp and Vectical is subject to step-therapy.  Aetna considers Taclonex, Taclonex Scalp and Vectical to be medically necessary for those members who meet the following step-therapy criteria:

    For Taclonex and Taclonex Scalp

    A documented trial of one month of concurrent use of BOTH calcipotriene solution /Dovonex or Tazorac AND topical betamethasone (either betamethasone dipropionate or betamethasone dipropionate, augmented).

    For Vectical

    A documented trial of one month of calcipotriene solution or Tazorac.

    If it is medically necessary for a member to be treated initially with a medication subject to step-therapy, the member's treating physician may contact the Aetna Pharmacy Management Precertification Unit to request coverage as a medical exception at 1-800-414-2386. (See criteria under section IV below.)

  3. Medical Exception Criteria
  4. Dovonex, Oxsoralen (lotion), Taclonex Scalp, Taclonex and Vectical are currently Not Covered Part D drugs under the Aetna Medicare Prescription Drug Plan.*  Therefore, they are excluded from coverage for members enrolled in prescription drug benefits plans that use a closed formulary, unless a medical exception is granted.  Aetna considers Dovonex, Oxsoralen (lotion), Taclonex Scalp, Taclonex and Vectical to be medically necessary for those members who meet the following criteria:

    For Dovonex and Oxsoralen (lotion)

    A. A documented:

    • Contraindication to one preferred alternative agent indicated for the member's condition OR
    • Intolerance to one preferred alternative agent indicated for the member's condition OR
    • Allergy to one preferred alternative agent indicated for the member's condition OR
    • Failure of an adequate trial of one month of one preferred alternative agent indicated for the member's condition

    For Taclonex and Taclonex Scalp

    A.   A documented:

    • Contraindication to BOTH calcipotriene solution /Dovonex or Tazorac AND betamethasone (either betamethasone dipropionate or betamethasone dipropionate, augmented ) OR
    • Intolerance to BOTH calcipotriene solution /Dovonex or Tazorac AND betamethasone (either betamethasone dipropionate or betamethasone dipropionate, augmented ) OR
    • Allergy to BOTH calcipotriene solution /Dovonex or Tazorac AND betamethasone (either betamethasone dipropionate or betamethasone dipropionate, augmented ) OR
    • Failure of an adequate trial of one month of concurrent use of  BOTH calcipotriene solution/Dovonex or Tazorac AND betamethasone (either betamethasone dipropionate or betamethasone dipropionate, augmented)

    For Vectical

    A.   A documented:

    • Contraindication to one alternative agent -- calcipotriene solution or Tazorac -- indicated for the member's condition OR
    • Intolerance to one alternative agent -- calcipotriene solution or Tazorac -- indicated for the member's condition OR
    • Allergy to one alternative agent -- calcipotriene solution or Tazorac -- indicated for the member's condition OR
    • Failure of an adequate trial of one month of one alternative agent -- calcipotriene solution or Tazorac --  indicated for the member's condition

Place of Service:

Outpatient

The above policy is based on the following references:
  1. DrugPoints® System ( www.statref.com) Thomson Micromedex, Greenwood Village, CO. Updated periodically.
  2. AHFS Drug Information® with AHFSfirstReleases®. ( www.statref.com), American Society Of Health-System Pharmacists®, Bethesda, MD. Updated periodically.
  3. DRUGDEX® System [Internet database]. Greenwood Village, Colo: Thomson Micromedex. Updated periodically.
  4. Drug Facts and Comparisons on-line. (www.drugfacts.com), Wolters Kluwer Health, St. Louis, MO. Updated periodically.
  5. PDR® Electronic Library™ [Internet database]. Greenwood Village, Colo: Thomson Micromedex. Updated periodically.
  6. 6.       Clinical Pharmacology [Internet database]. Gold Standard Inc. Tampa, FL. Updated periodically.
  7. Fick DM, Cooper JW, Wade WE, et al.  Updating the Beers criteria for potentially inappropriate medication use in older adults.  Arch Intern Med. 2003;163:2716-24.
  8. Zahn C, Sangl J, Bierman AS, et al.  Potentially inappropriate medication use in the community-dwelling elderly.  JAMA.  2001;286:2823-29.
  9. Lebwohl M, Tyring SK, Hamilton TK, et al: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-2013.
  10. Papp K, Bissonnette R, Krueger JG, et al: The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001; 45:665-674.
  11. Lebwohl M, Drake L, Menter A, et al: Consensus conference: Acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001; 45:544-553.
  12. Singh F & Weinberg JF: Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis. J Drugs Dermatol 2004; 3(2):141-143.
  13. Hanauer L: Treatment of plaque psoriasis. N Engl J Med 2001; 345(25):1854.
  14. Bashir SJ & Maibach HI: Alefacept (Biogen). Curr Opin Investig Drugs 2001; 2(5):631-634
Property of Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

February 20, 2009
email this page   
Aetna
Skip Past Footer Links
Company Information   |   Site Map Aetna.com Home   |   Help   |   Contact Us   |   Search
Web Privacy Statement   |   Legal Statement   |   Privacy Notices   |   Member Disclosure

Back to top